Cargando…

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

BACKGROUND: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rydzewska, Larysa H.M., Burdett, Sarah, Vale, Claire L., Clarke, Noel W., Fizazi, Karim, Kheoh, Thian, Mason, Malcolm D., Miladinovic, Branko, James, Nicholas D., Parmar, Mahesh K.B., Spears, Melissa R., Sweeney, Christopher J., Sydes, Matthew R., Tran, NamPhuong, Tierney, Jayne F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Ltd 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630199/ https://www.ncbi.nlm.nih.gov/pubmed/28800492 http://dx.doi.org/10.1016/j.ejca.2017.07.003

Ejemplares similares

The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience
por: Tierney, Jayne F, et al.
Publicado: (2015)

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
por: Vale, Claire L, et al.
Publicado: (2016)

A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials
por: Tierney, Jayne F., et al.
Publicado: (2021)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
por: Vale, C L, et al.
Publicado: (2018)

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials()
por: Vale, Claire L., et al.
Publicado: (2015)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
por: Burdett, Sarah, et al.
Publicado: (2019)

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
por: Goodman, O B, et al.
Publicado: (2014)

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
por: de Bono, Johann S., et al.
Publicado: (2016)

The need for a cultural shift from two-arm to multi-arm RCTS
por: Sydes, Matthew R, et al.
Publicado: (2013)

Assessing and improving the reliability of meta-analyses of hazard ratios derived from published time-to-event data
por: Tierney, Jayne, et al.
Publicado: (2013)

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study
por: Fukasawa, Satoshi, et al.
Publicado: (2018)

Sharing individual participant data: through a systematic reviewer lens
por: Rydzewska, Larysa H. M., et al.
Publicado: (2022)

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial
por: Parry, Marina A., et al.
Publicado: (2023)

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study
por: Suzuki, Hiroyoshi, et al.
Publicado: (2020)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Practical methods for incorporating summary time-to-event data into meta-analysis
por: Tierney, Jayne F, et al.
Publicado: (2007)

Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study
por: Tierney, Jayne F., et al.
Publicado: (2020)

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
por: Warde, Padraig, et al.
Publicado: (2011)

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2019)

Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective
por: Collier, Tony, et al.
Publicado: (2020)

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
por: Chi, K. N., et al.
Publicado: (2016)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)
por: O'Shaughnessy, J., et al.
Publicado: (2016)

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
por: Kim, Ki Bom, et al.
Publicado: (2015)

Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer
por: South, Annabelle, et al.
Publicado: (2016)

Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings
por: Noor, Nurulamin M., et al.
Publicado: (2020)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
por: Dearnaley, David P, et al.
Publicado: (2009)

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
por: Tolcher, A. W., et al.
Publicado: (2012)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
por: Xu, Ziyang, et al.
Publicado: (2022)

Analysis of survival data from trials with non-proportional hazards: an empirical comparison of methods
por: Royston, Patrick, et al.
Publicado: (2013)

First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change
por: Fisher, David J., et al.
Publicado: (2022)

Abiraterone Acetate
Publicado: (2012)

Sharing data from clinical trials: the rationale for a controlled access approach
por: Sydes, Matthew R, et al.
Publicado: (2015)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
por: Hu, Xin, et al.
Publicado: (2019)

Adding new experimental arms to randomised clinical trials: Impact on error rates
por: Choodari-Oskooei, Babak, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d2100cmg741krt7o5imfa8pvlp